Introduction
The increasing prevalence of gonorrhoea is widely acknowledged and of increasing concern to the health professions. Of additional concern are factors such as the developing resistance of Neisseria gonorrhoeae to available antibiotics and the failure of current methods, such as contact tracing, to reduce the rising incidence of infections. As a result there has recently been an increase in published reports in the use of prophylactic methods for sexually transmitted infections."18
Of the different methods of prophylaxis, vaginal preparations have received the most attention. Systemic and mechanical prophylaxis, while theoretically highly effective, have several disadvantages. The prophylactic use of systemic antibiotics may cause sensitisation with adverse reactions and also an increase in the number of resistant organisms. Although they avoid these side effects, condoms require the co-operation of the male partner and it is evident that this co-operation may not exist.'
As a result research has turned to the evaluation of local methods which can be used by the female partner. Of specific interest is chemoprophylaxis using commercially available products, such as that contraceptive products indeed have the potential to kill N gonorrhoeae.2 Further, Lee et a16 proposed that if 25% of the high-risk population consistently used a product which was 50% effective, a dramatic decrease in the prevalence of gonorrhoea could be seen within a short period of time.
These factors, together with the realisation that current management of gonorrhoea was not reducing the incidence of infections in Florida, prompted us to evaluate the potential of a chemoprophylactic vaginal contraceptive in reducing the incidence of gonorrhoea in women. Trained interviewers questioned all prospective study patients to ascertain their eligibility for inclusion in the project and to record pertinent medical and sociodemographic information. In addition, information was obtained on previous history of gonorrhoea and the number of sexual partners in the last 90 days.
FOLLOW UP
Patients were asked to return for three cultures for gonococci and further interviews at 30-day intervals beginning one month after treatment (that is, after admission to the study); they were given appointment cards with dates of future attendances. During reexamination, patients attending the Tampa clinic were asked how many sexual contacts they had had since the previous clinic visit and how often they had used the pessaries. Follow-up procedures were identical in both clinics. When patients failed to keep their follow-up appointments, they were telephoned or visited at home to ensure future attendance.
Before the study, established gonorrhoea control procedures in both cities were altered in three ways. Firstly, test-of-cure cultures were not performed; secondly, contact tracing of male patients with gonorrhoea was not carried out; and, thirdly, names of male sexual partners were not elicited from female patients; referral appointment cards were however distributed to the women for their contacts to attend the clinic.
The second phase of the study differed from the first only in that chemoprophylaxis was used for patients attending the clinic at Tampa; at the initial visit patients were given 24 vaginal pessaries,t instructed in the use and preventive aspects of the product, and strongly encouraged to insert the pessaries into the vagina between 15 and 60 minutes before sexual intercourse.
ADDITIONAL USE OF ANTIBIOTICS
In case study patients might have received additional antibiotics which could have affected gonococcal isolation rates patients who were treated with any medication other than APPG 4 8 megaunits (and probenecid) for any disease or condition other than gonorrhoea were excluded from the study. At follow up patients were questioned routinely about treatment for a venereal disease received elsewhere since the last visit; those reporting such treatment were also excluded from the study.
Similarly, respiratory disease in the general population during the study period could have affected the use of antibiotics. During phase 1 
Results
During phases 1 and 2, 570 and 675 women respectively were studied at the two clinics (table II) . Sociodemographic data showed strong similarities in the patients seen at both clinics during both phases (table III) . Analysis of comparative sociodemographic data showed both locations had similar study populations. The sexual behaviour of female patients was also very similar during both phases and at both locations (table IV) .
The percentage of women returning for at least one follow-up visit ranged from 64/o to 70%. There were no sociodemographic differences between those women who did and did not return.
REINFECTION RATES
During phase 1, the control period, the cumulative reinfection rates were similar during the first six and 420o in Orlando (X2 =0 01, P=0 94).
When chemoprophylaxis was introduced in the Tampa clinic, the reinfection rate over a 16-week period fell (fig 2) . The reinfection rate of 19% in Tampa was significantly lower than the 40%0 rate in Orlando (X2 =2-4, P=0 12). Interestingly, the reinfection rates were similar during the first six weeks (X2 = 0 00, P>0 98), but after that period they were significantly different (X2 = 9X46, P = 0-002).
Comparisons were also made of the reinfection rate between phase 1 and phase 2 for each clinic. ,-30 a dp 20- Multiple regression analysis produced several models forecasting reinfection, the most efficient of which consisted of two variables. A greater number of sexual contacts during the project period and a lower educational level were found to be significant predictors (P<0-05). In addition to showing that venereal disease education should be directed at those below the median educational level (11th grade) of study patients, this analysis indicates that clinic staff should interview patients who have a greater number of sexual contacts than average more intensively during subsequent interviews.
It was also seen that the women could be motivated to use a pessary; 65% of the women claimed that they sometimes used a pessary before sexual intercourse. The older patients used them more often than the younger ones.
The women atteinding the venereal disease clinic at Tampa during the study period constituted approximately 15% of the women in the greater Tampa area who were diagnosed as having gonorrhoea by all county physicians during the study. As expected the impact of reduced reinfection on reported gonorrhoea was minimal in the Tampa area during phase 2 compared with phase 1. Although previous gonorrhoea control procedures were also suspended at Orlando (control location), there was no significant change in the number of reported cases of female gonorrhoea for the greater Orlando area during the study.
Conclusion
The results of this study showed that reinfection rates were reduced when vaginal chemoprophylaxis was introduced, that women can be motivated to use a pessary, and that vaginal prophylaxis has a place in the control of gonorrhoea. These results are similar to those observed by Cutler et al, 8 who found that an over-the-counter vaginal contraceptive was effective in protecting against reinfection with gonorrhoea.
A third phase of the study in which chemoprophylaxis would be suspended at the Tampa clinic was planned but could not be carried out due to lack of resources. Further research in other clinics is encouraged. 
